B. Riley set a $10.00 price target on Amyris (NASDAQ:AMRS) in a research report released on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently weighed in on the company. HC Wainwright set a $15.00 price target on Amyris and gave the company a buy rating in a research note on Monday. BidaskClub upgraded Amyris from a hold rating to a buy rating in a research note on Wednesday, August 15th. Zacks Investment Research cut Amyris from a hold rating to a sell rating in a research note on Thursday, August 9th. Finally, ValuEngine upgraded Amyris from a buy rating to a strong-buy rating in a research note on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $9.13.

Shares of Amyris stock traded down $0.03 on Monday, reaching $7.41. 7,985 shares of the company were exchanged, compared to its average volume of 1,042,546. Amyris has a one year low of $2.82 and a one year high of $9.22. The stock has a market cap of $380.28 million, a P/E ratio of -2.44 and a beta of 0.18. The company has a quick ratio of 0.38, a current ratio of 0.42 and a debt-to-equity ratio of -0.24.

Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). The company had revenue of $24.81 million during the quarter, compared to analyst estimates of $37.52 million. During the same quarter in the previous year, the business posted ($1.32) EPS. The company’s revenue for the quarter was down 3.4% compared to the same quarter last year. sell-side analysts expect that Amyris will post -1.41 EPS for the current year.

In other Amyris news, insider John Melo sold 22,355 shares of the stock in a transaction on Monday, July 16th. The stock was sold at an average price of $6.61, for a total transaction of $147,766.55. Following the transaction, the insider now owns 748,908 shares in the company, valued at approximately $4,950,281.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Patrick Y. Yang acquired 10,000 shares of the stock in a transaction on Thursday, August 9th. The shares were purchased at an average price of $7.71 per share, for a total transaction of $77,100.00. Following the transaction, the director now directly owns 36,932 shares in the company, valued at $284,745.72. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 50,877 shares of company stock worth $393,161 and sold 8,824,625 shares worth $54,897,886. 21.80% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its position in Amyris by 3,109.9% during the 2nd quarter. BlackRock Inc. now owns 1,714,555 shares of the biotechnology company’s stock worth $10,955,000 after buying an additional 1,661,141 shares during the period. Millennium Management LLC increased its position in Amyris by 13.5% during the 2nd quarter. Millennium Management LLC now owns 278,748 shares of the biotechnology company’s stock worth $1,781,000 after buying an additional 33,085 shares during the period. Ardsley Advisory Partners increased its position in Amyris by 25.0% during the 2nd quarter. Ardsley Advisory Partners now owns 125,000 shares of the biotechnology company’s stock worth $799,000 after buying an additional 25,000 shares during the period. Bank of New York Mellon Corp increased its position in Amyris by 87.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 106,216 shares of the biotechnology company’s stock worth $678,000 after buying an additional 49,628 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in Amyris during the 1st quarter worth $655,000. Hedge funds and other institutional investors own 27.90% of the company’s stock.

Amyris Company Profile

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Recommended Story: Exchange-Traded Funds (ETFs)

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.